Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Seaport Therapeutics, Inc. (SPTX)

Seaport Therapeutics Q3 net loss widens to $26.4 million; cash $403.8 million

Negative Impact 3 of 5 earnings Written later

Seaport Therapeutics reported a third-quarter 2026 net loss of $26.4 million, up from $22.5 million a year earlier, as research and development and general and administrative expenses rose. The company had $403.8 million in cash, cash equivalents and investments at September 30, 2026, which it says will fund operations into 2029. The filing reports no revenue, so the loss is the main measure of results for shareholders.

Key points

  • Q3 2026 net loss was $26.4 million, or $0.49 per share, versus $22.5 million, or $9.43 per share, in Q3 2025.
  • R&D expenses rose to $23.9 million from $20.5 million, mainly due to Phase 2b BUOY-1 trial costs for GlyphAllo.
  • G&A expenses rose to $6.5 million from $5.0 million, mainly due to costs of operating as a public company.
  • Cash, cash equivalents and investments totaled $403.8 million at September 30, 2026, versus $233.7 million at December 31, 2025.

The filing

CompanySeaport Therapeutics, Inc. (SPTX)
Form8-K, current report
Filed with the SECNov 2, 2026, 7:03 AM ET
Accession number0001193125-26-442625

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.